TABLE 6.
In vivo hollow fiber assays to assess anti-tumor efficacy of TIR-199 (NSC:761526) in mice
Twelve cancer cell lines were tested in mice, representing the following tumor groups: colon (COLO 205, SW-620), skin/melanoma (LOX IMVI, MDA-MB-435, UACC-62), breast (MDA-MB-231), non-small cell lung (NCI-H23, NCI-H522), ovary (OVCAR-3, OVCAR-5), and CNS (SF-295, U251). These 12 cell lines represent a standard panel selected by the NCI-DTP based on good tumor growth performance in the hollow fiber assay. Cell lines were implanted (intraperitoneally or subcutaneously), and mice were treated (intraperitoneally) at 6.4 or 9.3 mg/kg/dose daily for 4 days, as described under “Experimental Procedures.” Values represent the percentage of cell growth. Underlined values indicate cell lines with ≥50% growth inhibition, which is considered a positive result to determine the total score. The total score for TIR-199 was 20 (intraperitoneal 2 × 8 cell lines = 16 and subcutaneous 2 × 2 cell lines = 4). Experiments were performed at the NCI-DTP. HF, hollow fiber; IP, intraperitoneal; SC, subcutaneous.
| Cell line | Percentage of cell growth |
||||
|---|---|---|---|---|---|
| HF implant (IP) 6.30 mg/kg (IP) | HF implant (IP) 9.40 mg/kg (IP) | HF implant (SC) 6.30 mg/kg (IP) | HF implant (SC) 9.40 mg/kg (IP) | Tumor group | |
| COLO 205 | 78 | 25 | 100 | 60 | Colon |
| SW-620 | 109 | 91 | 106 | 73 | Colon |
| LOX IMVI | 162 | 53 | 107 | 28 | Skin/melanoma |
| MDA-MB-435 | 44 | 24 | 80 | 48 | Skin/melanoma |
| UACC-62 | 115 | 88 | 114 | 106 | Skin/melanoma |
| MDA-MB-231 | 92 | 66 | 87 | 97 | Breast |
| NCI-H23 | 85 | 75 | 101 | 108 | Non-small cell lung |
| NCI-522 | 95 | 49 | 124 | 96 | Non-small cell lung |
| OVCAR-3 | 97 | 45 | 93 | 65 | Ovary |
| OVCAR-5 | 44 | 22 | 95 | 75 | Ovary |
| SF-295 | 72 | 48 | 95 | 77 | CNS |
| U251 | 97 | 54 | 115 | 97 | CNS |